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ing today need to 
be aware of the 
ways in which the 
current industry-
dominated climate 
may undermine the integrity of the sci-
entific process and, thus, may compro-
mise patient care. In the mental health 
field, corporate sponsorship bias can 
affect psychiatric taxonomy and clinical 
Practice Guidelines (CPG).  Financial 
conflicts of interest (FCOI) can occur 
when there are financial associations 
between researchers, authors, or panel 
members developing psychiatric diag-
nostic and treatment guidelines, and the 
pharmaceutical industry, or when ran-
domized clinical trials (RCTs) are indus-
try funded. Therefore, clinicians need to 
be especially vigilant about the informed 
consent process when patients are pre-
scribed psychotropic medications. As 
Past President, Elaine LeVine, Ph.D. 
noted in the December, 2007 issue of 
The Tablet, the issue of informed con-
sent is a particularly salient one for Divi-
sion 55 members:  
Psychologists adopting a scientist-
practitioner model are in an excel-
lent position to carefully analyze 
the research regarding the efficacy 
and safety of various drugs. Be-
cause we view education as part of 
our role as healers, we work with 
our patients to provide the exten-
sive informed consent that allows 
them to make knowledgeable deci-
sions about using medications, 
given a thorough understanding of 
the cost/benefit ratio. (p. 3) 
In order to be fully educated about the 
risk/benefit ratio of psychotropic medi-
cations, we must critically evaluate the 
diagnostic and treatment information 
that is being produced and disseminated.  
Psychiatric Taxonomy and the Phar-
maceutical Industry  
In 1952, the first official Diagnostic and 
Statistical Manual of Mental Disorders 
(DSM) was published by the American 
Psychiatric Association. Few outside the 
field had ever heard of what is now of-
ten referred to as the ―bible‖ of psychi-
atric disorders. Fewer still would have 
predicted that 58 years later there 
would be a firestorm of controversy 
over the proposed revisions to the 
DSM.  
In light of the DSM‘s clinical importance, 
the appearance of industry bias, let 
alone the reality, can undermine its in-
tegrity and weaken public trust. The 
concern about undue industry influence 
was heightened when it was discovered 
that the organization that produces the 
DSM, the American Psychiatric Associa-
tion, receives substantial drug industry 
funding, and the majority of the individu-
als who serve as diagnostic panel mem-
bers also have drug industry ties. My 
colleagues and I discovered that 100% of 
the individuals on two DSM panels, 
Schizophrenia and Psychotic Disorders, 
and Mood Disorders, had financial ties 
(e.g., served on speakers‘ bureaus, cor-
porate boards, received honoraria) with 
the pharmaceutical industry (Cosgrove, 
Krimsky, Vijayaraghavan, & Schneider, 
2006). The fact that all of the members 
of these panels had industry ties is prob-
lematic because psychopharmacology is 
the standard treatment in these two 
categories of disorders.  
To its credit, the American Psychiatric 
Association has required all DSM-V 
panel members to post financial disclo-
sure statements (http://www.dsm5.org). 
Indeed, the American Psychiatric Asso-
ciation has made a commitment to bet-
ter manage potential FCOI, and cer-
tainly this new disclosure requirement 
appears to be a step in the right direc-
tion. One would, therefore, expect to 
see a decrease in the number of indi-
viduals serving on the DSM-V panels 
who have corporate ties. However, as 
we reported in the New England Journal 
of Medicine last year, despite increased 
transparency, industry relationships with 
DSM panel members persist; approxi-
mately 68% of the DSM-V task-force 
members report having ties to the phar-
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maceutical industry (Cosgrove, 
Bursztajn, & Krimsky, 2009). This repre-
sents a relative increase of 20% over the 
proportion of DSM-IV task-force mem-
bers with such ties.  But it is not only 
task force members who have financial 
relationships with Big Pharma; of the 
137 DSM-V panel members who have 
posted disclosure statements, 77 (56%) 
reported industry ties, such as holding 
stock in pharmaceutical companies, 
serving as consultants to the drug indus-
try, or serving on drug company boards, 
which is no improvement over the 56% 
of DSM-IV members who were found to 
have such industry relationships. Some 
DSM-V panels still have a majority of 
members with industry ties. If financial 
conflicts of interest are not reduced, 
private-sponsor bias in research will be 
exacerbated. 
With concerns mounting about the 
American Psychiatric Association‘s fi-
nancial ties with the pharmaceutical in-
dustry, questions have been raised by 
patient advocacy groups, investigative 
journalists, clinicians and researchers as 
to whether the proposed changes for 
the DSM-V are evidence-based.  Because 
a DSM diagnosis influences treatment 
decisions, especially decisions about 
psychotropic medications, adding new 
disorders can have a significant impact 
on prescribing practices. Indeed, the 
lack of biological markers for psychiatric 
conditions renders the field vulnerable 
to industry influence. Specifically, the 
lack of biological markers opens the 
door for what some have referred to as 
―disease mongering‖ or ―widening the 
boundaries of treatable ill-
ness‖ (Moynihan, Heath, & Henry, 
2002).  In turn, this may allow pharma-
ceutical companies to apply for FDA 
approval of new medications that are 
actually ―me too‖ drugs, drugs that are 
neither more efficacious nor safer than 
those already on the market. (See Egli 
and Egli‘s excellent essay in the July, 
2007 Tablet on the FDA approval of 
Invega, then a new atypical antipsychotic 
that is essentially a patent extender). In 
fact, sometimes the iatrogenic harms of 
these medications may outweigh their 
benefits.  
My colleagues and I have been following 
the proposed revisions to the DSM. An 
example of a new disorder that expands 
diagnostic boundaries and would likely 
result in an increase in the number of 
individuals prescribed psychotropic 
medication, especially children and ado-
lescents, is "Attenuated Psychotic Symp-
toms Syndrome" (http://www.dsm5.org). 
This syndrome, proposed for inclusion 
in the DSM-V, describes symptoms of 
psychosis that are theorized to appear 
in individuals at risk for developing 
schizophrenia, before they are actually 
diagnosed with the disease. The idea is 
that if prodromal psychotic symptoms 
are diagnosed and treated early enough, 
it will be possible to prevent at-risk indi-
viduals from developing schizophrenia 
(Gobal, Cosgrove, & Bursztajn, in press). 
However, the data do not support this 
reasoning. Various studies have demon-
strated that only 16-30% of people with 
symptoms of psychosis end up develop-
ing schizophrenia later in life (McGorry 
et al., 2009; Yung et al., 2008). More-
over, it is not even clear that treatment 
with antipsychotic medications reduces 
their risk for developing schizophrenia 
any more than treatment with placebo 
(McGlashan et al., 2006). Based on these 
findings, and in light of the adverse side 
effects of antipsychotic medications, 
including movement disorders, weight 
gain, and diabetes, some researchers 
have concluded that the risk/benefit 
ratio does not justify treating those at 
risk for psychosis with these medica-
tions (De Koning et al., 2009; McGorry 
et al., 2009). We believe, therefore, that 
before the DSM-V adopts "Attenuated 
Psychotic Symptoms Syndrome," panel 
members need to provide further… 
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... evidence regarding the validity and 
reliability of this newly proposed cate-
gory (Gobal et al., in press).  
Are clinical Practices Guidelines 
(CPG) and Randomized clinical Trials 
(RCTs) industry influenced?  
As noted above, there are increasing 
concerns that the pharmaceutical indus-
try may be able to influence the defini-
tion of a mental health problem. There 
also is the concern that drug industry 
involvement (e.g., funding of clinical tri-
als, guideline authors serving on speak-
ers‘ bureaus of pharmaceutical compa-
nies) could affect CPG development. In 
2009, my colleagues and I published the 
results of a study that examined financial 
associations between the pharmaceuti-
cal industry and authors of three major 
CPG for Bipolar Disorder, Major De-
pressive Disorder and Schizophrenia. 
We found that 90% of the authors had 
financial ties to the pharmaceutical com-
panies that manufactured the drugs that 
were identified in the guidelines as rec-
ommended therapies for the respective 
mental illnesses; None of these financial 
associations were disclosed in the CPG 
(Cosgrove, Bursztajn, Krimsky, Anaya, & 
Walker, 2009). The results of this and 
other studies highlight the need for 
greater transparency and management 
of FCOI in the development of CPG.  
 
Because meaningful informed consent 
requires a full representation of adverse 
effects and accurate information on the 
efficacy of the recommended medica-
tions, clinicians rely upon results of 
RCTs as the ―gold standard‖ for evi-
dence-based medicine. Thus, it goes 
without saying that RCTs should be free 
of sponsor bias. However, in today‘s 
climate, should clinicians be wary about 
the ―evidence‖ being disseminated?  
Let‘s look at the recent research that 
addresses this question. Pitrou, 
Boutron, Ahmad, and Ravaud (2009) 
examined reporting and presentation of 
harm-related results in RCTs published 
in general medical journals with high-
impact factors. They concluded that 
reporting of harms continues to be in-
adequate. They found that information 
related to the severity of adverse events 
was not reported in 27.1% of RCTs, and 
withdrawal of patients because of ad-
verse events was not reported in 47.4% 
of RCTs. Another study also raises 
questions as to whether clinicians 
should unquestioningly accept the re-
sults of RCTs. Researchers studying 
financial conflict of interest in clinical 
trials of psychiatric medications found 
that, ―among the 162 randomized, dou-
ble-blind, placebo-controlled studies 
examined, those that reported conflict 
of interest were 4.9 times more likely to 
report positive results‖ (Perlis et al., 
2005). ―[T]he randomized trials agenda 
may need to reprogram its whole mis-
sion, including its reporting, toward bet-
ter understanding of harms‖ (Ioannidis, 
2009, p. 1739). 
Results of these and other studies have 
led some to question whether FCOI and 
marketing have triumphed over science. 
The under-reporting of negative results 
and publication bias, leading to unsub-
stantiated efficacy and safety data, may 
prevent clinicians from being able to 
fully inform their patients about the as-
sociated risks and benefits to taking a 
recommended medication.  
This is not to suggest that pharmaceuti-
cally-funded researchers intentionally 
misrepresent their findings in a pro-
industry way. Researchers are not al-
ways aware of the subtle ways in which 
their industry connections may influence 
their choice of language or influence 
their choice of which findings to high-
light. It would also not be fair to say that 
we can never trust industry-sponsored 
research. In fact, some studies have 
found that, ―the research methods of 
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trials sponsored by drug companies is at 
least as good as that of non-industry 
funded research, and in many cases bet-
ter‖ (Lexchin, Bero, Djulbegovic, & 
Clark, 2003, p. 1168). However, as this 
brief review of the literature shows, 
current disclosure requirements and the 
peer-review process cannot ensure that 
treatment recommendations published 
in high-impact medical journals or pro-
duced by professional organizations will 
be accurate, balanced, and free of cor-
porate sponsorship bias. 
Conclusion 
The field of psychiatry has been plagued 
by allegations that the pharmaceutical 
industry may be exerting an undue influ-
ence on the profession. For example, in 
2008 Senator Charles Grassley widened 
his series of hearings and investigations 
into financial associations between 
medicine and the pharmaceutical indus-
try by requiring the American Psychiat-
ric Association to provide, ―an account-
ing of industry funding that pharmaceuti-
cal companies and/or the foundations 
established by these companies have, 
including but not limited to grants, do-
nations, and sponsorship for meetings 
or programs‖ (Moran, 2008).  
The concerns about industry influence 
in organized psychiatry make Division 
55‘s goal of granting prescriptive author-
ity to all properly trained psychologists 
especially timely. As Dr. LeVine (2007) 
astutely pointed out, psychologists‘ 
training in the scientist-practitioner 
model is essential in being able to care-
fully and thoroughly assess the scientific 
evidence regarding the efficacy and 
safety of psychotropic medications. 
However, this training needs to be aug-
mented by incorporating a critical and 
reflective approach to psychiatric taxon-
omy, and to the treatment recommen-
dations disseminated in clinical Practice 
Guidelines. Consideration of the role 
that the funding source may have played 
in the research design, data analysis, or 
reporting of results, is essential. For 
example, we must ask questions such as: 
Were adequate outcome measures used 
in this RCT? Was the effect size clinically 
meaningful as well as statistically signifi-
cant? Was equipoise violated by com-
paring the new medication to a placebo 
rather than to a comparable drug al-
ready on the market? In terms of diag-
nosis, we must carefully examine the 
evidence when new DSM diagnoses are 
proposed or when changes in sympto-
matology are suggested, especially when 
these changes will have a direct and 
significant impact on prescribing prac-
tices.  
Some psychiatrists have found it difficult 
to understand how financial conflicts of 
interest in the field may increase bias in 
the diagnosis and treatment of mental 
illness. As Upton Sinclair stated, "It is 
difficult to get a man to understand 
something when his salary depends 
upon his not understanding 
it" (1935/1994, p. 109). Prescribing psy-
chologists take heed. 
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and Nurses to Improve the Reach 
and Quality of Primary Care. As 
the landmark health reform law 
goes into effect, bringing millions of 
uninsured Americans onto insur-
ance rolls over the next five years, 
demand for primary care services 
will increase; So, too, will demand 
for more accessible, effective, and 
efficient models of primary care. 
Rather than hiring more primary 
care physicians, many medical prac-
tices, health centers, and other 
primary care settings have been 
experimenting with innovative 
models of care that both extend 
the reach of primary care physi-
cians and increase the quality of 
ambulatory services... [bringing] 
pharmacists, social workers, 
nurses, and nurse practitioners to 
primary care practices.  With them 
comes a new set of skills that can 
improve care and lower costs for 
patients with depression, physical 
disabilities, and other conditions 
that have proven difficult to treat 
in primary care settings…. 
The Commonwealth Care Alliance 
invested heavily in the model – 
spending approximately $4 million 
on 25 practices, many of which are 
located in low-income, safety net 
clinics.  The investment, which 
covers the cost of hiring the nurse 
practitioners by the primary care 
practices and investing in infra-
structure such as electronic medi-
cal records, is more than offset in 
reductions in hospitalizations for 
preventable conditions as well as 
delays in nursing home place-
ments…. 
Dramatic Change Is Coming 
Over the next five years, we will wit-
ness the systematic implementation of 
what is perhaps the most significant so-
cial legislation enacted by the Congress 
since the Great Society programs of 
President Lyndon Johnson. Change is 
definitely coming. This could well be an 
extremely exciting era for our profes-
sion‘s prescribing psychologists. Those 
with vision and perseverance will thrive 
and flourish. 
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